Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.

Abstract

BACKGROUND:

To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy.

METHODS:

Two hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia.

RESULTS:

Among 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 ± 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 ± 2.8 mmHg (9.5%) to 6.4 ± 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity.

CONCLUSIONS:

Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.

• Authors: Kaidi Wang, Li Xu, Zhilan Yuan, Ke Yao, Junmei Zhao, Liang Xu, Aiwu Fang, Mingzhi Zhang, Lingling Wu, Jian Ji, Jiamin Hou, Qing Liu, Xinghuai Sun
• Journal: BMC ophthalmology (BMC Ophthalmol) Vol. 14 Pg. 21 (Feb 25 2014) ISSN: 1471-2415 [Electronic] England
• PMID: 24568617 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Chemical References

• Amides
• Antihypertensive Agents
• Cloprostenol
• Bimatoprost

Topics

• Adult
• Aged
• Amides (adverse effects, pharmacology, therapeutic use)
• Antihypertensive Agents (adverse effects, pharmacology, therapeutic use)
• Bimatoprost
• China
• Cloprostenol (adverse effects, analogs & derivatives, pharmacology, therapeutic use)
• Conjunctival Diseases (chemically induced)
• Female
• Glaucoma, Open-Angle (drug therapy, physiopathology)
• Humans
• Hyperemia (chemically induced)
• Intraocular Pressure (drug effects, physiology)
• Male
• Middle Aged
• Ocular Hypertension (drug therapy, physiopathology)
• Prospective Studies